aztreonam has been researched along with Kidney Diseases in 13 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter comparative study was carried out to evaluate the efficacy of aztreonam and gentamicin in 186 patients with symptomatic renal or urinary tract infections." | 9.06 | Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections. ( Albertazzi, A; Bonadio, M; Fusaroli, M; Lotti, T; Miano, L; Salvia, G; Sasdelli, M; Ventriglia, L; Villa, G; Zucchelli, P, 1989) |
| "Aztreonam was administered to 30 patients, ages 0." | 5.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| "A multicenter comparative study was carried out to evaluate the efficacy of aztreonam and gentamicin in 186 patients with symptomatic renal or urinary tract infections." | 5.06 | Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections. ( Albertazzi, A; Bonadio, M; Fusaroli, M; Lotti, T; Miano, L; Salvia, G; Sasdelli, M; Ventriglia, L; Villa, G; Zucchelli, P, 1989) |
| "Plasma concentrations of aztreonam follow a 2-compartment open model with a distribution half-life of 0." | 2.39 | Clinical pharmacokinetics of aztreonam. An update. ( Mattie, H, 1994) |
| "12 L/h/kg), and terminal half-life is 1." | 2.37 | Clinical pharmacokinetics of aztreonam. ( Mattie, H, 1988) |
| " Renal insufficiency may significantly impair the elimination of aztreonam, thus requiring modification of the dosage regimen." | 2.37 | Review of the clinical pharmacology of the monobactam antibiotic aztreonam. ( Swabb, EA, 1985) |
| " The mean of beta elimination phase half-life ranged from 2 h in normal subjects to 6 h in anephric patients." | 1.27 | Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. ( Bolton, ND; Bolton, WK; Mihindu, JC; Scheld, WM; Spyker, DA; Swabb, EA, 1983) |
| "Aztreonam was administered to 30 patients, ages 0." | 1.27 | Aztreonam in the treatment of severe urinary tract infections in pediatric patients. ( Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) |
| "6 to 121 ml/min per 70 kg, and the half-life ranged from 1." | 1.27 | Pharmacokinetics of aztreonam in patients with gram-negative infections. ( Apicella, MA; Cafarell, RF; Janicke, DM; Jusko, WJ; Parker, SW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (61.54) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lipp, HP | 1 |
| Watson, AJ | 1 |
| Stout, RL | 1 |
| Whelton, A | 1 |
| Mihindu, JC | 1 |
| Scheld, WM | 1 |
| Bolton, ND | 1 |
| Spyker, DA | 1 |
| Swabb, EA | 2 |
| Bolton, WK | 1 |
| Mattie, H | 2 |
| Segre, G | 1 |
| Urso, R | 1 |
| Konishi, K | 1 |
| Suzuki, H | 1 |
| Saruta, T | 1 |
| Deguchi, N | 1 |
| Fugono, T | 1 |
| Nagasaka, H | 1 |
| Inagaki, O | 1 |
| Nasu, M | 1 |
| Nakagawa, K | 1 |
| Nishian, Y | 1 |
| Hiraoka, K | 1 |
| Syono, T | 1 |
| Azuma, M | 1 |
| Hirabayashi, T | 1 |
| Mori, H | 1 |
| Albertazzi, A | 1 |
| Bonadio, M | 1 |
| Fusaroli, M | 1 |
| Lotti, T | 1 |
| Miano, L | 1 |
| Salvia, G | 1 |
| Sasdelli, M | 1 |
| Villa, G | 1 |
| Zucchelli, P | 1 |
| Ventriglia, L | 1 |
| Rusconi, F | 1 |
| Assael, BM | 1 |
| Boccazzi, A | 1 |
| Colombo, R | 1 |
| Crossignani, RM | 1 |
| Garlaschi, L | 1 |
| Rancilio, L | 1 |
| Donadio, C | 1 |
| Tramonti, G | 1 |
| Garcea, G | 1 |
| Lorusso, P | 1 |
| Lucchetti, A | 1 |
| Giordani, R | 1 |
| Pierotti, R | 1 |
| Falcone, G | 1 |
| Bianchi, C | 1 |
| Janicke, DM | 1 |
| Cafarell, RF | 1 |
| Parker, SW | 1 |
| Apicella, MA | 1 |
| Jusko, WJ | 1 |
4 reviews available for aztreonam and Kidney Diseases
| Article | Year |
|---|---|
[Revival of selected well-tried antibiotics. Special features of the antiinfective agents penicillin G, fosfomycin, aztreonam and colistin].
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Colistin; Fosfomycin; Humans; Kidney Disease | 2012 |
Clinical pharmacokinetics of aztreonam. An update.
Topics: Absorption; Aztreonam; Blood Proteins; Cystic Fibrosis; Half-Life; Humans; Injections, Intramuscular | 1994 |
Clinical pharmacokinetics of aztreonam.
Topics: Aging; Aztreonam; Bacterial Infections; Drug Administration Routes; Humans; Kidney; Kidney Diseases; | 1988 |
Review of the clinical pharmacology of the monobactam antibiotic aztreonam.
Topics: Anti-Bacterial Agents; Aztreonam; Child; Drug Administration Schedule; Feces; Gram-Negative Aerobic | 1985 |
2 trials available for aztreonam and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.
Topics: Adult; Aztreonam; Drug Evaluation; Female; Half-Life; Humans; Injections, Intravenous; Kidney Diseas | 1991 |
Multicenter comparative study of aztreonam and gentamicin in the treatment of renal and urinary tract infections.
Topics: Adult; Aged; Ambulatory Care; Aztreonam; Bacterial Infections; Female; Gentamicins; Humans; Injectio | 1989 |
7 other studies available for aztreonam and Kidney Diseases
| Article | Year |
|---|---|
The intrarenal distribution of aztreonam in healthy and diseased kidneys: clinical therapeutic implications.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Dogs; Female; Humans; Hydrogen-Ion Concentration; Kidney; | 1984 |
Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Chromatography, High Pressure Liquid; Drug Administration S | 1983 |
The sojourn time and its use in pharmacology.
Topics: Aztreonam; Blood Pressure; Gentamicins; Half-Life; Humans; Kidney Diseases; Models, Biological; Nore | 1991 |
[Pharmacokinetics of aztreonam on hemodialysis].
Topics: Aged; Aztreonam; Female; Humans; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Models | 1990 |
Aztreonam in the treatment of severe urinary tract infections in pediatric patients.
Topics: Adolescent; Aztreonam; Child; Child, Preschool; Citrobacter; Enterobacter; Enterobacteriaceae Infect | 1986 |
Azthreonam in the treatment of urinary tract infection: evaluation of efficacy, renal effects and nephrotoxicity.
Topics: Adult; Aged; Aztreonam; Enzymes; Female; Humans; Injections, Intramuscular; Kidney Diseases; Kidney | 1987 |
Pharmacokinetics of aztreonam in patients with gram-negative infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Blood Proteins; Female; Gram-Ne | 1985 |